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Due to the possibility to cure the disease, treatment duration in HCV is limited to a
maximum of 48 weeks. The lengths of use of direct acting agents (DAA=s) are
significantly different: 12 weeks with telaprevir vs. 24, 32 or 44 weeks with boce-
previr. These factors make the implementation of futility rules in economic models
critical. OBJECTIVES: To provide an insight on the proper application of the futility
rules in economic evaluations of DAA=s. METHODS: A decision tree model was
developed to assess cost-efficacy for each DAA, considering 4 patient types: naïve,
relapsers, partial responders, and null responders. Average acquisition costs have
been estimated with and without the use of futility rules; if these rules are used,
corresponding salvage treatment costs were included. The efficacy of triple therapy
treatment was defined by patient type based on each DAA’s summary of product
characteristics. Cost per patient with sustained virological response (SVR) and the
number of cured and not cured patients was calculated with a fixed budget.
RESULTS: For a 10 million EUR investment in each patient type for either DAA,
using telaprevir offers maximum cured (726 vs. 587) and minimum non-cured
patients (399 vs. 517) if futility rules are not considered. If the futility rules are used,
there are still maximum cured patients (759 vs. 734) and minimum non-cured
patients (450 vs. 697) when telaprevir is used. We performed one-way and two-way
sensitivity analyses and the overall conclusion does not change vs. boceprevir.
CONCLUSIONS: Telaprevir offers maximum cured and minimum non-cured pa-
tients regardless of the futility rule consideration when compared to boceprevir. If
stopping rules are considered in economic evaluations for the treatment of HCV, an
appropriate horizon timeline should also be considered to capture future unavoid-
able costs of non-cured patients: salvage treatment and/or potential disease pro-
gression.
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OBJECTIVES: Invasive Fungal Infections (IFIs) present a major issue in clinical prac-
tice, due to their high morbidity and mortality rates. In a pivotal multicentre, ran-
domized clinical trial posaconazole prophylaxis prevented IFIs more effectively
than did either fluconazole or itraconazole, and improved overall survival. The aim
of this study was to perform an economic evaluation of the afore-mentioned ther-
apeutic strategies for IFI prophylaxis in neutropenic patients, in the Greek health
care setting.METHODS:A decision analytic model was developed, which described
the course of neutropenic patients under posaconazole or standard azole (flucona-
zole or itraconazole) treatment. The effectiveness data for each treatment regimen
were derived from published results of a pivotal, multicentre, randomized clinical
trial. The cost and health care resources utilization data used, depict Greek clinical
practice and are derived from official Greek sources. In order to obtain some of the
model imputs, expert opinion from Greek Hematologists specializing in treating
IFIs, was also used. RESULTS: Prophylaxis with Posaconazole resulted in fewer IFIs
(0,05 vs. 0,11 per patient) compared to treatment with fluconazole or itraconazole,
during the first 100 days from initiation of prophylaxis treatment. The cost per
avoided IFI with Posaconazole was 6,455€, while the cost for every incremental life
year gained (LYG) was estimated at 24,196€. Extensive sensitivity analyses (one-
way and probabilistic) corroborated the base-case results. CONCLUSIONS: : The
utilization of Posaconazole for prophylaxis of IFIs in hematology patients with
neutropenia is a therapeutic strategy that provides superior clinical efficacy, while
being cost-effective compared to alternative therapies.
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OBJECTIVES: To estimate the disease burden and economic impact of the 10-valent
pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV13) in Finland
based on recently generated vaccine efficacy/effectiveness data. To date, vaccine efficacy
of the second generation pneumococcal conjugate vaccines (PCVs) on invasive pneumo-
coccal disease (IPD) and pneumonia has been extrapolated based on 7-valent PCV (PCV7)
efficacy data and serotype distribution. Impact of PCVs on IPD and pneumonia is now
observed inpost-marketingsettings inseveralcountriesandtheeffectivenessofPHiD-CV
against IPD has recently been demonstrated in a clinical trial in Finland. METHODS: A
Markov cohort model was used to estimate the clinical and cost burden of pneu-
mococcal and NTHi-related diseases in a birth cohort over lifetime and to measure
the clinical and economic impact of PHiD-CV compared with PCV13 in Finland.
Age-specific incidences of IPD, pneumonia and acute otitis media (AOM) and direct
medical costs were calculated and used as input data. Only the direct effect of
vaccination was assessed. Outcomes were measured by reduction in disease bur-
den, costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness
ratio. RESULTS: The model predicts that PHiD-CV and PCV13 may have a similar
impact on IPD and pneumonia in a pediatric population. PHiD-CV is estimated to
prevent an additional 26,576 AOM cases and 2,502 myringotomy procedures versus
PCV13 in a country with a birth cohort of 57,000 infants. This translates in an
additional reduction of medical costs by EUR 8,470,547 (discounted with 3%). Cost-
effectiveness analysis showed that PHiD-CV provides 135 more QALYs (discounted)
while saving cost compared with PCV13. Universal infant vaccination with
PHiD-CV provides more HE benefits than PCV13. CONCLUSIONS: Nation-wide in-
fant vaccination with PHiD-CV in Finland is projected to improve health outcomes
and be a cost-saving strategy. Funding: GlaxoSmithKline Biologicals SA.
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OBJECTIVES: Chickenpox is an infectious disease caused by the varicella-zoster virus
(VZV) which is recognized as a public health problem for its high infectivity that can lead
to serious complications and high costs both for society and health system. Published
studies indicate that in Italy about 500,000 people are affected by varicella each year. This
analysis estimates the incremental cost-effectiveness ratio (ICER) of replacing MMR vac-
cineby introducingMMRVvaccine inthecurrentschedule in Italy.Thehigherriskof fever
episodes and febrile seizures associated with MMRV compared with MMR vaccination
and the conservative assumption on exogenous immunity boosting on zoster incidence
were taken into account.METHODS: An age-structured dynamic model was used to
simulate the evolution of varicella and herpes zoster, both in current schedule and
with replacement of MMR by MMRV with a lifetime horizon. Two scenarios were
evaluated on the basis of first and second dose of vaccination coverage: 85% and
70% for the first scenario, 70% and 50% for the second scenario. It was assumed that
MMR would be completely replaced by MMRV within 5 years. RESULTS: For both
scenarios tested at the fifth year the ICER was 13,765 and 12,911 €/QALY respec-
tively for the first and second scenario. There were significant savings for outpa-
tient, hospitalisation and indirect costs. Varicella cases avoided following the com-
plete implementation of MMRV (in 5 years) were respectively 677,738 and 537,584.
CONCLUSIONS: This analysis, that considers benefits and risks of MMRV vaccines,
indicates that the implementation of MMRV would provide a benefit in terms of
cases and costs avoided and is likely to be cost-effective. From the NHS perspective
the ICER supports the introduction of MMRV. Benefits of vaccination increase in
correspondence to high vaccination coverage.
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OBJECTIVES: To analyze the cost-effectiveness of mass primovaccination of new-
borns in the Slovak Republic with BCG vaccine against tuberculosis compared to
the cost-effectiveness of selective primovaccination of specific groups, as well as to
there being no vaccination at all.METHODS: To compare cost-effectiveness, meth-
ods were chosen as to determine direct cost of illness and minimization of costs
from the perspective of health insurance companies. Additionally, the closely re-
lated parameter of direct costs needed to prevent one case of active tuberculosis in
children aged 0 to 14 years was analyzed. The own adapted model was used.
RESULTS: Data used were obtained from the Public Health Authority of the Slovak
Republic, National Tuberculosis Registry, State Institute for Drug Control, Statisti-
cal Office of the Slovak Republic, Ministry of Health, and from Health Insurance
Companies. We assumed that the vaccine will have a 15-year effect, at an average
effectiveness of 63.3% in preventing active tuberculosis. The costs for preventing
one case of active tuberculosis in children aged 0 to 14 years would be € 794.69 lower
if mass vaccination of newborns is applied than if all vaccination was to be discon-
tinued. For selective vaccination of newborns, the cost of preventing one case of
active tuberculosis in children aged 0 to 14 years would be € 440.02 lower than if all
vaccination were to be discontinued. Finally, mass vaccination of newborns results
in the cost of preventing one case of active tuberculosis in children aged 0 to 14
years being € 1 731.75 lower than for selective vaccination. CONCLUSIONS: The
most advantageous strategy for the state would be to implement mass vaccination
of newborns against tuberculosis. A shift to selective vaccination would only be
beneficial if the costs for treatment of tuberculosis were to decrease dramatically.
The least useful strategy would be to discontinue vaccination.
PIN48
COST-EFECTIVENESS ANALYSIS OF DARUNAVIR VERSUS ATAZANAVIR, EACH
IN COMBINATION WITH EMTRICITABINE AND TENOFOVIR, FOR THE
MANAGEMENT OF NAIVE ANTI-RETROVIRAL HIV INFECTED PATIENTS, UNDER
THE BELGIAN SOCIAL SECURITY PERSPECTIVE
Santos M1, Stenut S2, Ferraq W3, Legrand JC4, Tilleul P5, Borget I6
1Institut Gustave Roussy, Paris, Paris, France, 2Hopital Civil Charleroi, Charleroi, Belgium,
3Hôpital Mohamed VI, Marrakech, Morroco, Marrakech, Morocco, 4Hopital Civil Charleroi,
Charleroi, Charleroi, Belgium, 5Groupe hospitalier Pitié-Salpêtrière, paris, France, 6Institut
Gustave Roussy, Paris, France
OBJECTIVES: Although not directly compared, both Atazanavir and Darunavir are
possible options for the treatment of naive HIV-infected patients, as the third agent
(Ritonavir-boosted protease-inhibitor), to be used together with two nucleoside-
analogue, reverse-transcriptase inhibitors. The objective of this study was to eval-
uate the incremental cost-effectiveness ratio (ICER) of Darunavir compared to
Atazanavir in naive HIV-infected patients, according to the Belgian third party
payer perspective. METHODS: A cost-effectiveness model was developed to com-
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pare the two strategies, each using a Tenofovir-based backbone treatment. Effec-
tiveness was measured by virologic response, defined as the percentage of patients
with  50 viral copies/ml, based on a systematic review of recently published
prospective trials. Costs were estimated according to Belgian tariffs. Only direct
costs were considered, and were expressed in Euros (€). The time-horizon was of 48
weeks. A probabilistic sensitivity analysis was conducted to evaluate the robust-
ness of the results. RESULTS: Two prospective phase III trials were selected for
efficacy evaluation: data for Darunavir were extracted from the ARTEMIS trial (Mills
et cols.), whereas data for Atazanavir were extracted from the CASTLE trial (Molina
et cols.). Both compared the respectives drugs to Lopinavir. Based on an indirect
comparison, the rate of virologic response after 48 weeks of follow up was 84% (95%
CI: 82-86%) for Darunavir and 78% (95% CI: 76-80%) for Atazanavir, while total costs
were 5868,84€ and 4821,60€, respectively. The ICER was 18.011,04€ for Darunavir.
Sensitivity analysis showed that ICER depends mainly on the uni costs of the drugs,
as well as on their efficacy. However, it is relatively independant from side effects
and deaths related to treatment. CONCLUSIONS: Our results show that Darunavir,
used as the third agent (protease inhibitor), compared to Atazanavir, may be more
cost-effective for the treatment of naïve HIV-infected patients, in Belgium.
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OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. The elderly is a high risk (HR) population to develop IPD and this risk is raised
in the presence of chronic illness. This study aims to perform cost-effectiveness
analysis of 13-valent pneumococcal conjugated vaccine (PCV13) in elderly HR, from
a public payer perspective in Brazil. METHODS: A Markov model was developed to
simulate IPD outcomes in elderly HR after vaccination with PCV13 versus PPSV23
and no vaccination, with regard to associated direct costs in a 10-year time horizon.
Effectiveness parameters are avoided cases of IPD, meningitis, pneumonia, and
bacteremia. Medical costs included hospital days, medical personnel time, outpa-
tient visits, diagnostic tests and medications. Clinical data and costs were ex-
tracted from literature, presented in 2011USD. RESULTS: For an 1,000,000 patients
cohort, PCV13 avoided [14,159;14,885] bacteremia, [1,119;1,327] meningitis,
[190,831;198,098] hospitalized pneumonia, [153,569;150,599] non-hospitalized
pneumonia, and [56,102;58,686] IPD deaths, versus [PPSV23;no vaccination] respec-
tively. Medical and vaccination costs for PCV13 versus PPSV23 and no vaccination
were 7,901,973.76 BRL, 8,823,681.28 USD, and 8,327,792.71 USD, respectively. PCV13
was the dominant alternative in this cost-effectiveness analysis. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant com-
pared to PPSV23 and no vaccination in elderly high risk population.
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OBJECTIVES: Hepatitis C is a disease with significant economic burden to health
care systems. Two recently approved protease inhibitors –telaprevir (TVR) and
boceprevir (BOC)- are expected to change the current treatment algorithm, since
their addition to peginterferon and ribavirin (PR) is associated with significantly
improved clinical outcomes compared to PR alone. This analysis aims to evaluate
the cost-effectiveness of a triple regimen with telaprevir (TVRPR) compared to
one with boceprevir (BOCPR) from the Greek National Health Service perspective.
METHODS: A decision analytic model based on treatment pathways and efficacy
data from four phase III clinical trials (Advance, Sprint-2, Realize and Respond-2)
was used to assess the cost-effectiveness of TVRPR and BOCPR . Clinical out-
come was measured in terms of sustained virologic response (SVR) rates. Drug
costs were estimated based on available EU prices in March 2012. We estimated the
average cost per cured (SVR) patient and ICERs over treatment naïve and experi-
enced patients and over the overall HCV G1 population (with a ratio of 1 to 4).
Treatment stopping rules were not considered in this analysis. One way sensitivity
analysis was performed over the proportion of naïve patients. Resource allocation
implications were also considered under a hypothetical fixed budget scenario.
RESULTS: The average cost per cured patient in the overall HCV G1 population was
€46.635 for TVRPR and €56.146 for BOCPR. In treatment naïve patients it was
€38.868 for TVRPR and €42.983 for BOCPR, whereas in treatment experienced
patients it was €48.966 and €59.902 respectively. In terms of ICERs TVRPR was
associated with lower costs and higher SVR rates, with an ICER of - €10.403 per
cured patient gained in the overall patient population. Results were robust in sen-
sitivity analysis. CONCLUSIONS: TVRPR was projected to be cost-effective com-
pared to BOCPR, allowing for more patients to be cured under a hypothetical fixed
budget.
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OBJECTIVES: After infection, varicella-zoster-virus can reactivate as herpes zoster
(HZ), a painful skin rash most commonly among the elderly. A HZ-complication is
long-lasting pain after rash disappearance: postherpetic neuralgia (PHN). A vaccine
has been licensed in Europe to prevent HZ/PHN in individuals aged 50 years. To
support decision-making concerning a possible vaccination-recommendation in
Germany we performed a health economic evaluation.METHODS:We developed a
5-state Markov-model with age-specific transition probabilities. We compared a
vaccination-strategy to a scenario without vaccination targeting different popula-
tion-cohorts aged 50 in Germany (50-54, 55-59, etc.) to identify the most cost-
effective strategy. Besides the payer-perspective (PP), the societal-perspective (SP)
- covering in addition to direct also indirect costs - was considered. Country-spe-
cific demographic, epidemiological, and cost-of-illness input-data were utilized.
We assumed a vaccine price of 100 Euro/dose, lifelong duration of protection, and
20% vaccination-coverage. All monetary amounts were in Euro 2010. The cycle-
length was a quarter, and the model ended when individuals died. The discount-
rate was 3% for both, outcomes and costs. Outcomes were number of HZ- and
PHN-cases avoided. Results were presented as incremental cost-effectiveness ra-
tios (ICERs) and number-needed-to-vaccinate (NNV). Univariate deterministic sen-
sitivity-analyses (DSA) were performed. RESULTS: When targeting a cohort aged
50-54 years, preventing one HZ-case costs approximately 400€ from PP and approx-
imately 280€ from SP. In this age-cohort the NNV was 6. DSA showed that results
were most sensitive to target-age at vaccination, vaccine price, and discount rate.
When increasing the target-age to 85 year-olds, ICERs were 3,646€ (PP) and 3,634€
(SP) per adverted HZ-case, respectively, indicating a lower cost-effectiveness of
vaccination in this age-cohort; NNV increased to 37. When considering prevention
of PHN-cases ICERs became less favourable. CONCLUSIONS: Vaccination appears
as valuable prevention-option especially when targeting the 50-54-years age-co-
hort. However, target-age at vaccination, price, and duration of protection will be
key-factors in decision-making.
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OBJECTIVES: To study economic efficiency of three regimes for pharmacotherapy
of acute bronchitis. Apart from classic therapy the first and second regimes in-
cluded the usage of drugs of human recombinant interferon-a2b in the form of
suppositories. METHODS: Patients suffering from acute bronchitis were randomly
split into three groups comprising 50 people each. The first group got classic ther-
apy (mucolytics, vitamins, alkaline drinks, heat reduction drugs) and suppositories
of interferon-a2b (genferon) by 1 mln ME injected rectally twice a day for the period
of 5 days. The second group was cured with interferon (viferon) by 1 mln ME twice
a day for the period of 5 days. The third group got the classic therapy only. The
pharmacoeconomical analysis estimated the general treatment cost and minimi-
zation of expenses. RESULTS: The average period of overcoming acute bronchitis
took 9 days for the first two groups and 12 days for the third group. The average
period of temporary work disability lasted for 7 [6; 8] days for the first two groups
and 10 [9; 12] days for the third group. The general cost for the first group amounted
to € 168.9, 167.1 for the second group and € 230.4 for the third group. The minimi-
zation of expenses reached € 61.5 for the first group and € 63.3 for the second one in
comparison with the classic method. Considering minimal costs of drugs the min-
imization of expenses amounted to € 56.5 and € 61 respectively. Considering ex-
penses for antibacterial therapy the minimization of expenses when taking into
account the average costs of drugs reached € 62.1 and € 64.4 respectively.
CONCLUSIONS: As a result, the pharmacotherapy of acute bronchitis when using
interferon is more justified than the classic method of therapy.
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OBJECTIVES: To assess the cost-effectiveness of maternal triple-drug ART or infant
nevirapine to reduce HIV transmission during breastfeeding from HIV-infected
Malawian mothers, not meeting treatment guidelines for their own health. Strat-
egies were evaluated at two entry points into the health system: 1) time of delivery,
for mothers who have not accessed ART antenatally, and 2) antenatally.
METHODS: Cost-effectiveness was evaluated in terms of health care costs per HIV
transmission averted, life-years gained, quality adjusted life-years (QALYs) gained,
and disability adjusted life-years (DALYs) averted. The risks of HIV transmission
associated with the interventions were taken from the Kesho Bora and BAN stud-
ies. Antenatal regimens were 1) zidovudine (ZDV); 2) ZDV, lamivudine (3TC), lopi-
navir/ritonavir; and (3) no antenatal regimen. The postnatal regimens were 1) ma-
ternal antiretrovirals (ZDV, 3TC, lopinavir/ritonavir); 2) infant nevirapine (NVP);
and 3) no extended post-natal prophylaxis. Scenario analyses included: alternate
drug combinations and prices, and earlier antenatal initiation. RESULTS: For moth-
ers presenting at delivery, infant NVP during breastfeeding is likely to be consid-
ered cost-effective. Incremental cost-effectiveness ratios (ICERs) compared to stan-
dard of care are $264 per HIV transmission averted, $15 per life-year saved, $16 per
QALY and $15 per DALY averted. For mothers presenting antenatally, antenatal
ZDV plus infant NVP during breastfeeding appears cost-effective. ICERs compared
to ZDV plus standard of care are $667 per HIV transmission averted, $37 per life-
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